Latest news with #localjournalism
National Post
7 days ago
- Business
- National Post
Covalon Reports Fifth Consecutive Quarter of Positive Earnings
This advertisement has not loaded yet, but your article continues below. Year-To-Date Revenue Grew 21% and Year-To-Date Adjusted EBITDA Increased by 57% THIS CONTENT IS RESERVED FOR SUBSCRIBERS Enjoy the latest local, national and international news. Exclusive articles by Conrad Black, Barbara Kay and others. Plus, special edition NP Platformed and First Reading newsletters and virtual events. Unlimited online access to National Post. National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on. Daily puzzles including the New York Times Crossword. Support local journalism. SUBSCRIBE FOR MORE ARTICLES Enjoy the latest local, national and international news. Exclusive articles by Conrad Black, Barbara Kay and others. Plus, special edition NP Platformed and First Reading newsletters and virtual events. Unlimited online access to National Post. National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on. Daily puzzles including the New York Times Crossword. Support local journalism. REGISTER / SIGN IN TO UNLOCK MORE ARTICLES Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account. Share your thoughts and join the conversation in the comments. Enjoy additional articles per month. Get email updates from your favourite authors. THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK. Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account Share your thoughts and join the conversation in the comments Enjoy additional articles per month Get email updates from your favourite authors MISSISSAUGA, Ontario — Covalon Technologies Ltd. (the 'Company' or 'Covalon') (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced its fiscal 2025 second quarter results for the period ended March 31, 2025, along with a number of important recent achievements and highlights. Brent Ashton, Covalon's Chief Executive Officer, reported, 'In the past few months, the Covalon team has delivered on several of our key priorities that have led to expanded sales with new and existing customers, new agreements with key strategic partners, and exciting new clinical evidence generation. In the first six months of our 2025 fiscal year, Covalon has: Grown revenue by 21%, Grown Gross Profit by 12% Reduced Operating Expenses by 8% Increased Adjusted EBITDA by 57% As stated last quarter, we fully anticipated our U.S. Advanced Wound Care sales channel to have a sequential quarter decline in Q2. This is not consequential, as we have a clear line of sight via in-house orders, forecasts and recent strategic partner sell out trends, to a strong Q3 and second half. Covalon recently signed a major distribution agreement with our longstanding strategic partner, Paul Hartmann USA, for ColActive Plus® and ColActive Plus® with Silver advanced wound care dressings. Covalon's U.S. Advanced Wound Care sales channel has been an important growth driver for the Company, and our first half of FY'25 was double the revenue from the same period two years ago. Our U.S. Vascular Access and Surgical Consumables sales channel had excellent sequential quarterly growth of 19%, and year to date is up 46% vs. the prior year, led by significant growth from Covalon's VALGuard® Vascular Access Line Guard product. New clinical evidence on Covalon's VALGuard® will be presented at two prestigious scientific meetings in the fall and is advancing through the publication process in a major, well-regarded academic journal. This will be a significant accelerator to the surge in adoption that we have seen with major U.S. hospitals. We have also made significant headway in our International sales channel, and our Q2 revenue of $2.3 million marked our highest quarterly revenue for International in more than five years, and has grown 44% year to date. In a volatile and complex global trade environment, Covalon's North American-centric manufacturing strategy has yielded no tariff-related costs to date, and the Company sees the current tariff environment as a competitive advantage. Covalon is in a stronger position than it has ever been, with profitable operations and a clean balance sheet with more than $18 million in cash and no debt. We have retained a highly regarded financial and strategic advisor to identify merger and acquisition opportunities and unlock value for all shareholders. Our accelerated focus on market development is generating exciting results. I see a clear path for Covalon to become a major player in the lucrative healthcare spaces we operate in.' Q2 FY'25 Financial Highlights Revenue of $7.6 million led by strong growth in the U.S. Vascular Access and Surgical Consumables business as well as the International business Adjusted EBITDA of $0.6 million – Covalon's 5 th consecutive quarter of profitability consecutive quarter of profitability Strong free cash flow generation of $0.6 million Recent Covalon Achievements and Highlights Conference Call Scheduled A conference call and webcast to discuss Covalon's fiscal 2025 Q2 financial results will be held on Wednesday, May 28 at 8:30am Eastern Time. To view, listen to, and participate in the live webcast, please follow the link below: To listen and participate via the conference call, please dial: North American Toll-Free: 1-800-549-8228 Local (Toronto): 289-819-1520 Local (New York): 646-564-2877 Conference ID: 92114 Participants will be able to ask questions of Company management during the Q&A portion of the conference call. A recording of the call will also be available on under Financials on the Investors tab. For the three-month period ending March 31, 2025: Total revenue decreased to $7,585,968 compared to $8,388,022 in the same period of the prior year. The decrease in product revenue was primarily driven by a normalization of channel inventory for one of the Company's Advanced Wound Care U.S. strategic partners. The Company reported a gross margin of 55% for the period, compared to 63% in the same period of the prior year. The year-over-year decrease in gross margin was primarily driven by changes in geographic and product mix. The operating expenses were relatively consistent at $3,857,686, compared to $3,827,704 in the same period of the prior period. The operations department covers expenses related to quality control, quality assurance, production, and regulatory activities. Operations expenses increased slightly to $451,471 compared to $423,239 in the same period of the prior year. This increase was primarily due to higher employee training costs incurred in the current period, which helped to strengthen operational efficiency and compliance with regulatory standards. Research and development expenses decreased to $320,459 compared to $450,510 in the same period of the prior year primarily due to lower patent & trademark costs as the costs can vary by quarter and fiscal year due to the timing and region of the renewals. Sales and marketing expenses were flat at $1,250,162, compared to $1,262,960 in the same period of the prior year. The Company continues to optimize sales and marketing strategies to accelerate demand for the company's products. General and administrative expenses increased to $1,835,594 compared to $1,690,995 in the same period of the prior year, reflecting higher professional service fees. Wages, benefits, and consulting fees (for all departments) included non-cash share-based compensation expenses of $65,540, down from $81,464 in the prior year. These costs reflect outstanding stock options and deferred share units (DSUs) and their respective fair values. For the six-month period ending March 31, 2024: Total revenue increased to $15,751,948 compared to $13,076,667 in the same period of the prior year, with double digit growth in the 3 main sales channels the company is focused on – the U.S. Advanced Wound Care sales channel, the U.S. Vascular Access and Surgical Consumables sales channel and the International sales channel. Gross Margin decreased to 58% compared to 62% in the same period for the prior year. During the six months ended March 31, 2025, the Company recorded a $114,645 release in inventory provision due to revised obsolescence estimates, compared to an inventory provision of $482,095 recorded during the six months ended March 31, 2024. Gross margin fluctuates as a result of the mix of products sold in any given quarter, or year, by product type and geography. Operating expenses decreased to $7,537,484 compared to $8,147,756 in the same period of the prior year. The majority of this decrease, is attributable to reduced sales and marketing expenses. Additional spending reductions were realized across operations, research and development, and general and administrative functions, reflecting the Company's continued focus on cost efficiency and disciplined expense management. Operations expenses decreased to $822,540 from $1,053,952 in the same period of the prior year. The reduction was primarily attributable to the timing of expenses related to product development initiatives that were recognized in the prior year. Research and development expenses decreased to $693,798 compared to $761,921 in the same period for the prior year, mainly due to lower patent and trademark costs. Sales and marketing costs decreased to $2,459,982 compared to $2,909,263 in the same period of the prior year, due primarily to lower staffing levels. General and administrative expenses increased to $3,561,164 compared to $3,422,620 in the same period in the prior year, due primarily to higher spending on professional service fees. Wages, benefits, and consulting fees (for all departments) include a non-cash compensation expense of $156,063, down from $197,393 in the prior year. These costs reflect outstanding stock options and deferred share units (DSUs) and their respective fair values. The following audited table presents Covalon's consolidated statements of operations for the three-month and six-month periods ended March 31, 2025, and 2024. Three months ended March 31, Six months ended March 31, 2025 2024 2025 2024 Revenue Product $7,585,968 $8,388,022 $15,663,908 $12,963,789 Development and consulting services – – 5,826 56,640 Licensing and royalty fees – 25,588 82,214 56,238 Total revenue 7,585,968 8,413,610 15,751,948 13,076,667 Cost of sales 3,446,462 3,103,148 6,617,976 4,917,668 Gross profit 4,139,506 5,310,462 9,133,972 8,158,999 Operating expenses Operations 451,471 423,239 822,540 1,053,952 Research and development activities 320,459 450,510 693,798 761,921 Sales, marketing and agency fees 1,250,162 1,262,960 2,459,982 2,909,263 General and administrative 1,835,594 1,690,995 3,561,164 3,422,620 3,857,686 3,827,704 7,537,484 8,147,756 Finance expenses (income) (147,319) 22,340 (188,387) 12,376 Loss/(gain) on finance lease receivable – – 149,690 (610,008) Net income $429,139 $1,460,418 $1,635,185 $608,875 Other comprehensive income (loss) Amount that may be reclassified to profit or loss Foreign currency translation adjustment (40,155) 576,178 1,810,299 188,905 Total comprehensive income $388,984 $2,036,596 $3,445,484 $797,780 Income per common share Basic income per share (Note 16) $0.02 $0.06 $0.06 $0.02 Diluted income per share (Note 16) $0.02 $0.06 $0.06 $0.02 Non-GAAP Financial Measures This press release makes reference to certain non-GAAP measures. These measures are not recognized or defined measures under IFRS Accounting Standards, do not have standardized meaning prescribed by IFRS Accounting Standards and are therefore unlikely to be comparable to similar measures presented by other companies. Rather, these measures are provided as additional financial information to complement those IFRS Accounting Standards measures by providing further understanding of our results of operations from management's perspective. Accordingly, these measures should not be considered in isolation or as a substitute for analysis of our financial information reported under IFRS Accounting Standards. The non-GAAP financial measures, adjustments, and reasons for adjustments should be carefully evaluated as these measures have limitations as analytical tools and should not be used in substitution for an analysis of the Company's results under IFRS Accounting Standards. We use non-GAAP measures including 'Adjusted Gross Margin' and 'Adjusted EBITDA' to provide investors with supplemental measures of our operating performance and thus highlight trends in our core business that may not otherwise be apparent when relying solely on IFRS Accounting Standards measures. We believe that securities analysts, investors and other interested parties frequently use non-GAAP measures in the evaluation of issuers. Our management also uses non-GAAP measures in order to facilitate operating performance comparisons from period to period, to prepare annual operating budgets and forecasts and to determine components of management compensation. The following non-GAAP financial measures are presented in this news release, and a description of the calculation for each measure is included below: Adjusted Gross Margin is defined as gross profit before operating expenses, plus depreciation and amortization included in cost of sales, plus inventory provision amounts. Adjusted EBITDA as earnings (loss) before interest expense (income), depreciation and amortization, stock-based compensation, inventory provisions (reversals), gain (loss) on finance lease receivable, and loss (gain) on disposal of property and equipment. You should also be aware that the Company may recognize income or incur expenses in the future that are the same as, or similar to some of the adjustments in these non-GAAP financial measures. Because these non-GAAP financial measures may be defined differently by other companies in our industry, our definitions of these non-GAAP financial measures may not be comparable to similarly titled measures of other companies, thereby diminishing their utility. The table below provides a reconciliation of gross profit before operating expenses under IFRS Accounting Standards in the consolidated financial statements to Adjusted Gross Margin for the three-month and six-month periods ended March 31, 2025, and 2024. Management believes that Adjusted Gross Margin is useful in assessing the performance of the Company's ongoing operations and its ability to generate cash flows from period to period. The adjusting items below are considered to be outside of the Company's core operating results, and these items can distort the trends associated with the Company's ongoing performance, even though some of those expenses may recur. Three months ended March 31, Six months ended March 31, 2025 2024 2025 2024 Gross profit $4,139,506 $5,310,462 9,133,972 $8,158,999 Add: Depreciation and amortization 43,728 58,322 113,353 110,870 Add: Inventory provisions (reversals) – 674,866 (114,645) 482,095 Adjusted Gross Margin 4,183,234 6,043,650 9,132,680 8,751,964 Adjusted Gross Margin (%) 55% 72% 58% 67% The table below provides a reconciliation of net income under IFRS Accounting Standards in the unaudited condensed consolidated interim financial statements to Adjusted EBITDA for the three-month and six-month periods ended March 31, 2025, and 2024. Management believes that these non-GAAP measures are useful in assessing the performance of the Company's ongoing operations and its ability to generate cash flows to fund its cash requirements from period to period. The adjusting items below are considered to be outside of the Company's core operating results, and these items can distort the trends associated with the Company's ongoing performance, even though some of those expenses may recur. Three months ended March 31, Six months ended March 31 2025 2024 2025 2024 Net income $429,139 $1,460,418 $1,635,185 $608,875 Add: Finance expense (gains) (147,319) 22,340 (188,387) 12,376 Add: Depreciation and amortization 233,621 247,756 490,746 487,950 Add: Stock based compensation 65,540 81,464 156,063 197,393 Add: Inventory provisions (reversals) – 674,866 (114,645) 482,095 Add: Impairment of intangible asset – 101,577 – 176,025 Add: (Gain)/loss of finance lease receivable – – 149,690 (610,008) Adjusted EBITDA $580,981 $2,588,421 $2,128,650 $1,354,706 Covalon is a leading medical device company dedicated to improving patient outcomes through innovative and compassionate medical products and technologies. Our expertise spans advanced wound care, vascular access, and surgical consumables, with a strong focus on enhancing healing, reducing healthcare-associated infections (HAIs), and protecting skin integrity. Our solutions are designed for patients and made for care providers. The Company is listed on the TSX Venture Exchange (COV) and trades on the OTCQX Market (CVALF). To learn more about Covalon, visit our website at Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as 'seek', 'anticipate', 'plan', 'estimate', 'expect', 'intend', or variations of such words and phrases or state that certain actions, events, or results 'may', 'could', 'would', 'might', 'will' or 'will be taken', 'occur', or 'be achieved'. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts, but instead represent management's expectations, estimates, and projections regarding future events. Forward-looking statements involve risks and uncertainties, including, but not limited to, the factors described in greater detail in the 'Risks and Uncertainties' section of our management's discussion and analysis of financial condition and results of operations for the year ended September 30, 2024, which is available on the Company's profile at any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company assumes no obligation to update or alter any forward-looking statements, whether as a result of new information, further events, or otherwise, except as required by law. (1) See 'Non-GAAP Measures' below, including for a reconciliation of the non-GAAP measures used in this release to the most comparable IFRS Accounting Standards measures. To learn more about Covalon, please contact: Investor Relations, Covalon Technologies Ltd. Email: investors@ Website: This advertisement has not loaded yet.
Yahoo
25-05-2025
- Yahoo
25-year-old Florida man killed in hit-and-run in Wellfleet. Police are investigating.
A 25-year-old Florida man was killed an apparent hit-and-run pedestrian strike late Saturday night in Wellfleet, according to police. Around 11:37 p.m., the Wellfleet Police and Fire Departments went to Ocean View Drive in the area of Long Pond Road after receiving a call about a pedestrian lying in the roadway. First responders found the man, who appeared to be struck by a vehicle. Officers and fire personnel performed life-saving measures, but he was pronounced dead at the scene. Police believe the suspect vehicle is a pickup truck or SUV with front-end damage, according to the statement, and said the vehicle was not present when first responders arrived and is believed to have fled the scene after the incident. The deceased man's name is being withheld pending notification of next of kin. Zane Razzaq writes about housing and real estate. Reach her at zrazzaq@ Follow her on X @zanerazz. Thanks to our subscribers, who help make this coverage possible. If you are not a subscriber, please consider supporting quality local journalism with a Cape Cod Times subscription. Here are our subscription plans. This article originally appeared on Cape Cod Times: Wellfleet hit-and-run kills 25-year-old Florida man: Police
National Post
22-05-2025
- Business
- National Post
Could smarter task management help solve a productivity slump?
Save on lifetime access to Swatle All-in-One AI Assistant. Photo by StackCommerce Reviews and recommendations are unbiased and products are independently selected. Postmedia may earn an affiliate commission from purchases made through links on this page. This article was created by StackCommerce. Postmedia may earn an affiliate commission from purchases made through our links on this page. THIS CONTENT IS RESERVED FOR SUBSCRIBERS Enjoy the latest local, national and international news. Exclusive articles by Conrad Black, Barbara Kay and others. Plus, special edition NP Platformed and First Reading newsletters and virtual events. Unlimited online access to National Post. National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on. Daily puzzles including the New York Times Crossword. Support local journalism. SUBSCRIBE FOR MORE ARTICLES Enjoy the latest local, national and international news. Exclusive articles by Conrad Black, Barbara Kay and others. Plus, special edition NP Platformed and First Reading newsletters and virtual events. Unlimited online access to National Post. National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on. Daily puzzles including the New York Times Crossword. Support local journalism. REGISTER / SIGN IN TO UNLOCK MORE ARTICLES Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account. Share your thoughts and join the conversation in the comments. Enjoy additional articles per month. Get email updates from your favourite authors. THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK. Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account Share your thoughts and join the conversation in the comments Enjoy additional articles per month Get email updates from your favourite authors A growing number of Canadian businesses are facing the same modern paradox: the more digital tools they adopt, the more fractured and complicated their workflows become. Instead of a single platform to streamline everything, we have the chaos of Slack for communication, Trello for tasks, Google Sheets for tracking and Zoom for meetings. At a time when productivity is slipping in many workplaces, the push for greater efficiency is becoming more urgent. And many business leaders are realizing that piecing together a dozen apps isn't solving the problem. That's where platforms like Swatle are trying to change the game for the better. Unlike legacy task managers or chat apps, Swatle is an all-in-one AI-powered system that reduces the cognitive load of managing work. It centralizes tasks, conversations, timelines and file-sharing into a single intuitive hub, and adds AI support to help you work through it faster. What does that look like in practice? A manager can type in a project idea, and Swatle will help break it into tasks with time estimates. Or if you need a quick status report, you can ask AI instead of scheduling another meeting. Trying to clean up a rambling Slack message? Swatle can rewrite it clearly and professionally. And instead of toggling between Gantt charts, Kanban boards and spreadsheets, teams can visualize progress in any way that suits them all in one place. Swatle is the kind of tool that makes sense for growing companies trying to scale without bloating their staff or budget. A lifetime license is currently available for $84, making it a cost-effective alternative to pricey SaaS subscriptions. In a competitive economy, speed and clarity matter. And while AI can't replace human strategy, it might be just the kind of assistant every team needs to stay sharp, stay focused and stop drowning in digital noise. Pick up a lifetime subscription to Swatle for $84 while it's on sale. What: Limited-time sale Price: $84 (Was: $335) Where to buy: Lifetime access to Swatle Prices subject to change.
National Post
09-05-2025
- General
- National Post
These air mattresses with a built-in pump are comfy and convenient
This advertisement has not loaded yet, but your article continues below. The best self-inflating air mattresses. Photo by Amazon Reviews and recommendations are unbiased and products are independently selected. Postmedia may earn an affiliate commission from purchases made through links on this page. I've owned an air mattress for more years than I can count. For me, it's just one of those things that are worthwhile having on hand. Growing up it came in handy for out-of-town family visits and now similarly it's pulled out anytime there are more people than beds. THIS CONTENT IS RESERVED FOR SUBSCRIBERS Enjoy the latest local, national and international news. Exclusive articles by Conrad Black, Barbara Kay and others. Plus, special edition NP Platformed and First Reading newsletters and virtual events. Unlimited online access to National Post. National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on. Daily puzzles including the New York Times Crossword. Support local journalism. SUBSCRIBE FOR MORE ARTICLES Enjoy the latest local, national and international news. Exclusive articles by Conrad Black, Barbara Kay and others. Plus, special edition NP Platformed and First Reading newsletters and virtual events. Unlimited online access to National Post. National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on. Daily puzzles including the New York Times Crossword. Support local journalism. REGISTER / SIGN IN TO UNLOCK MORE ARTICLES Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account. Share your thoughts and join the conversation in the comments. Enjoy additional articles per month. Get email updates from your favourite authors. THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK. Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account Share your thoughts and join the conversation in the comments Enjoy additional articles per month Get email updates from your favourite authors I wasn't always a huge fan though and have had my fair share of bad air mattress experiences. In some cases, the air mattress would begin sinking or losing air throughout the night; it would get punctured simply by moving it around too much, and in some cases it was just too noisy and uncomfortable. However, over time the quality and technology surrounding air mattresses has improved, with many even having built-in air pumps for added convenience. Personally, I've now had the same one for about 10 years and it's still going strong. Air mattresses are typically more durable, comfortable, supportive and long-lasting than they ever have been. If you're in the market for a new one ahead of the summer camping season or need one for unexpected guests, check out our guide to highly-rated self-inflating air mattresses below. Product reviews, deals, roundups and interviews to help you make better buying decisions. By signing up you consent to receive the above newsletter from Postmedia Network Inc. Please try again SoundAsleep Dream Series Air Mattress with Comfort Coil Technology & Internal High Capacity Pump. Photo by Amazon Equipped with ComfortCoil Technology, a SureGrip bottom, an extra thick, waterproof flocked top and dual chamber construction, this air mattress provides durability, comfort and enough support to ensure you stay asleep all night. The patented 1-click internal pump makes it easy to inflate and deflate in under four minutes. Size option(s): Twin, Twin XL, Queen, King Height option(s): 19' Weight limit: 500 pounds (Queen size) Price: $202+ Where to buy: Amazon King Koil Luxury Air Mattress with High Speed Built-in Pump. Photo by AMAZON With enhanced coil technology, the highest quality materials and internal layering, the King Koil air mattress feels just like a traditional bed. The built-in speed pump also makes it easy to adjust the firmness level as needed – it can fully inflate and deflate a queen-size air mattress in just two minutes. The air-filled coils and layering also help support the spine, ensuring maximum comfort. Made of durable PVC with a skid resistant bottom, the mattress is also waterproof and resistant to wear and tear. Size option(s): Twin, Full, Queen, California King Height option(s): 20' Weight limit: 600 pounds (Queen size) Price: $160+ Where to buy: Amazon Intex Dura-Beam Deluxe Comfort-Plush High-Rise Air Mattress. Photo by AMAZON Proof that higher prices don't always mean better results. This affordable air mattress has a unique edge construction making it durable, supportive and lighter than a traditional airbed. It also features lumbar support for full body support with fiber-tech construction further providing comfort. This advertisement has not loaded yet, but your article continues below. Size option(s): Twin, Full, Queen Height option(s): 13', 18', 22' Weight limit: 600 pounds (Queen size) Price: $80+ Where to buy: Amazon Coleman All-Terrain Double-High Airbed with 120V Pump, Queen. Photo by CANADIAN TIRE A heavy-duty airbed geared with Puncture Guard technology perfect for outdoor use, but can also be used indoors. With features including a leak-free air tight system, strong coil construction and a bonded fabric surface, this air mattress is durable, convenient and long-lasting while also providing comfort. Size option(s): Queen Height option(s): 15' Weight limit: 800 pounds Price: $135 Where to buy: Canadian Tire Elegear Memory Foam Sleeping Pad. Photo by AMAZON For those who may not love the feel of just an air mattress, this hybrid foam and air option may be the answer. It's made from supportive memory foam with a built-in electric pump that inflates in under one minute. The fabric is breathable, sweat-absorbing, heat-insulating, tear-proof and skin-friendly adding to the comfort. Size option(s): Single, Full, Twin Height option(s): 3.1' Weight limit: 800 pounds (Full) Price: $140+ Where to buy: Amazon Shopping Essentials, a category written by research-obsessed shopping fanatics, is now on Explore in-depth product reviews, expert recommendations and exciting collaborations — plus get behind-the-scenes info on your favourite brands and trending products — learn more here or sign up for our newsletter.
